Our Legacy

CSL Behring and our parent company, CSL, continue to build on a long legacy of innovation in patient care. CSL Behring traces its beginnings to the 1904 founding of Behringwerke, a company established by Emil von Behring, the first recipient of the Nobel Prize in Medicine. In 1916, our parent company, CSL Limited, was founded to supply vaccines to the people of Australia. Each independently evolved over the years, but never strayed from their core promise, to meet the commitments and exceed the expectations of the patients they served. In 2004, the two came together to form CSL Behring, a worldwide leader in providing plasma therapies and their recombinant equivalents to improve the quality of life for people with rare and serious diseases. 

For more than a century, we have earned a reputation as a passionate yet responsible organization driven to care for patients, and our future has never looked brighter.

Leading the Way on Rare & Serious Diseases

We are committed to saving and improving the lives of people with rare and serious diseases worldwide.

Learn More
Giving Back

Helping our patient communities is part of our corporate responsibility.

Learn More

Our Directors & Executives enable us to deliver on our promise patients.

Learn More

Get our latest news in your inbox

First name
Last name


You have now been added
to the CSL Behring news list